Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
There is currently an urgent need for low cost and well tolerated intralesional agents for
the management of in transit and cutaneous melanoma metastases that are unsuitable for, or
resistant to, other therapies. This pilot study will determine whether intralesional
injections of the sclerosant polidocanol into intransit and cutaneous melanoma lesions shows
promise for efficacy, safety and ease of use that will enable this inexpensive and widely
available agent to undergo further evaluation.